[go: up one dir, main page]

JOP20180027A1 - بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها - Google Patents

بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها

Info

Publication number
JOP20180027A1
JOP20180027A1 JOP/2018/0027A JOP20180027A JOP20180027A1 JO P20180027 A1 JOP20180027 A1 JO P20180027A1 JO P20180027 A JOP20180027 A JO P20180027A JO P20180027 A1 JOP20180027 A1 JO P20180027A1
Authority
JO
Jordan
Prior art keywords
polypeptide
ligand
binding domain
plasma membrane
methods
Prior art date
Application number
JOP/2018/0027A
Other languages
English (en)
Inventor
Peter Emtage
Levi Rupp
Stephen Santoro
Scott Coyle
Original Assignee
Cell Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Design Labs Inc filed Critical Cell Design Labs Inc
Publication of JOP20180027A1 publication Critical patent/JOP20180027A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتم تقديم طرق و تراكيب لتحديد موقع البروتينات بشكل عكسي إلى الجزء الخارجي من سطح الخلية. يمكن أن تشتمل التراكيب الواردة هنا على الأحماض النووية التي تُشفر البولبيبتيدات المعنية و مجال ربط جزىء الارتباط (LBD) لمستقبل الهرمون النووي. عند إضافة جزىء الارتباط، يمكن للبوليبيبتيد أن يتموضع للجانب الخليوي الخارجي لغشاء البلازما. إزالة جزىء الارتباط يمكن أن يؤدي الى إزالة البوليبيبتيد من سطح الخلية. في بعض التجسيدات، يمكن لتركيبة حمض نووي تتضمن LBD أن تندمج في بوليبيبتيد يتضمن مجال ربط لمولد مضاد (على سبيل المثال، مستقبل مولد مضاد مخلط). في بعض التجسيدات، يمكن إدخال مثل هذا البوليبيبتيد في خلية الثدييات، عند دخول جزىء الارتباط للخلية، يتموضع مجال ربط مولد المضاد في البوليبيبتيد للجانب الخليوي الخارجي لغشاء البلازما و عند إزالة جزىء الارتباط يُزال مجال ربط مولد المضاد في البوليبيبتيد من الجانب الخليوي الخارجي لغشاء البلازما . تم تقديم تطبيقات طبية تشمل السيطرة على سمية خلايا CAR T.
JOP/2018/0027A 2017-03-28 2017-03-28 بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها JOP20180027A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477733P 2017-03-28 2017-03-28
US201762587262P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
JOP20180027A1 true JOP20180027A1 (ar) 2019-01-30

Family

ID=62090037

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0027A JOP20180027A1 (ar) 2017-03-28 2017-03-28 بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها

Country Status (15)

Country Link
US (2) US11111310B2 (ar)
EP (2) EP4516308A2 (ar)
JP (3) JP2020512009A (ar)
KR (4) KR102659440B1 (ar)
CN (1) CN110678480A (ar)
AU (4) AU2018244592C1 (ar)
BR (1) BR102018006205A2 (ar)
CA (1) CA3058262A1 (ar)
ES (1) ES2996737T3 (ar)
IL (1) IL269433A (ar)
JO (1) JOP20180027A1 (ar)
SG (2) SG10201912408WA (ar)
TW (2) TWI811212B (ar)
UY (1) UY37644A (ar)
WO (1) WO2018183551A1 (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49355A (fr) * 2017-03-27 2020-02-05 Hoffmann La Roche Formats de récepteurs de liaison d'antigène améliorés
US11485789B2 (en) * 2017-11-12 2022-11-01 Jay H. Choi Modular, controlled single chain variable fragment antibody switch
US20240122980A1 (en) * 2019-10-18 2024-04-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of tim-3 cytoplasmic tail in chimeric antigen receptors
CN111995689B (zh) * 2020-08-27 2023-05-05 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
CN114149510B (zh) * 2021-10-29 2024-01-30 上海鑫湾生物科技有限公司 一种条件控制的可剪接嵌合抗原受体分子及其应用
KR20240112623A (ko) 2023-01-12 2024-07-19 엘지디스플레이 주식회사 표시 장치
WO2025045752A1 (en) * 2023-08-25 2025-03-06 T-Knife Gmbh Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP3700791B2 (ja) * 1994-05-26 2005-09-28 小野薬品工業株式会社 Ｆａｓ抗原融合蛋白、その蛋白をコードするＤＮＡ、そのＤＮＡを含むベクター、そのベクターで形質転換された宿主細胞、そのベクターを有効成分とする治療剤、およびその宿主細胞を用いるスクリーニング方法
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
EP0910648A1 (en) * 1996-04-15 1999-04-28 The Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain g-protein-coupled receptor compositions and methods
JP2002153287A (ja) * 2000-11-24 2002-05-28 Daicel Chem Ind Ltd 内分泌撹乱物質結合領域を細胞の表層に有する微生物およびその応用方法
US7150971B2 (en) 2001-05-21 2006-12-19 The Regents Of The University Of California Membrane-resident steroid receptors and methods of use thereof
EP1912069A3 (en) * 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US20060040354A1 (en) 2004-07-20 2006-02-23 O'keefe Theresa L Novel polyadenylation signal for use in expression vectors
DOP2006000116A (es) * 2005-05-19 2007-01-31 Schering Ag Sistema mejorado de expresión regulada y sus usos.
CN101292160A (zh) * 2005-05-26 2008-10-22 达娜-法勃肿瘤研究所公司 Muc1-依赖性的抗-雌激素抗性的调节
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
PE20121530A1 (es) 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112013002578A2 (pt) 2010-08-03 2019-05-14 Abbvie Inc. imunoglobinas de domínio variável duplo e usos das mesmas
DK3300745T3 (da) 2013-02-15 2019-11-04 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
EP2968502B1 (en) * 2013-03-14 2020-08-26 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
EP3104866A4 (en) * 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
US20170081411A1 (en) * 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2015179801A1 (en) * 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
WO2016073456A1 (en) * 2014-11-04 2016-05-12 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor
KR102624023B1 (ko) * 2015-02-24 2024-01-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 결합-촉발된 전사 스위치 및 이들의 이용 방법
SG11201707652WA (en) * 2015-03-30 2017-10-30 Intrexon Corp Ligand inducible polypeptide coupler system
AU2016313082B2 (en) * 2015-08-24 2022-03-31 Cellectis Chimeric antigen receptors with integrated controllable functions
WO2017120546A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Conditionally active heterodimeric polypeptides and methods of use thereof
EP3443096B1 (en) * 2016-04-15 2023-03-01 Novartis AG Compositions and methods for selective expression of chimeric antigen receptors

Also Published As

Publication number Publication date
US11993660B2 (en) 2024-05-28
KR20240019863A (ko) 2024-02-14
BR102018006205A2 (pt) 2021-03-23
KR20220002751A (ko) 2022-01-06
JP2020512009A (ja) 2020-04-23
CA3058262A1 (en) 2018-10-04
IL269433A (en) 2019-11-28
ES2996737T3 (en) 2025-02-13
KR102475696B1 (ko) 2022-12-09
JP2022058725A (ja) 2022-04-12
SG11201908618SA (en) 2019-10-30
US20210395386A1 (en) 2021-12-23
CN110678480A (zh) 2020-01-10
US20180319890A1 (en) 2018-11-08
EP3601330A1 (en) 2020-02-05
JP7433348B2 (ja) 2024-02-19
KR20190133734A (ko) 2019-12-03
KR20230004870A (ko) 2023-01-06
AU2018244592B2 (en) 2021-03-11
TW201840590A (zh) 2018-11-16
TWI811212B (zh) 2023-08-11
AU2018244592C1 (en) 2021-07-08
US11111310B2 (en) 2021-09-07
KR102659440B1 (ko) 2024-04-24
AU2023200894A1 (en) 2023-03-23
SG10201912408WA (en) 2020-02-27
EP4516308A2 (en) 2025-03-05
AU2024227182A1 (en) 2024-10-31
AU2021203626B2 (en) 2023-03-09
AU2021203626A1 (en) 2021-07-01
UY37644A (es) 2018-10-31
TW202409071A (zh) 2024-03-01
EP3601330B1 (en) 2024-11-13
AU2018244592A1 (en) 2019-10-03
AU2023200894B2 (en) 2024-07-11
EP3601330C0 (en) 2024-11-13
WO2018183551A1 (en) 2018-10-04
JP2024054208A (ja) 2024-04-16

Similar Documents

Publication Publication Date Title
JOP20180027A1 (ar) بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
MX2019000863A (es) Usos de vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.
MX2023000082A (es) Composiciones y metodos para la expresion selectiva de proteinas.
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
WO2014116846A3 (en) Methods and compositions for modulating an immune response
SG10201913583QA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
PH12020550240A1 (en) D-domain containing polypeptides and uses thereof
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
GB2549632A (en) Fusion protein comprising three binding domains to 5TA and CD3
EP4434997A3 (en) Delivery of negatively charged proteins using cationic lipids
SG10201805411YA (en) Chimeric antigen receptors
WO2014164348A3 (en) Modified caspase polypeptides and uses thereof
MY185678A (en) Drug related transgene expression
MX2023010640A (es) Péptidos neoantigénicos transmembranales.
MD4548B1 (ro) Polipeptide care se leagă de CX3CR1
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
MX2018015596A (es) Proteina de fusion entre el factor de viabilidad de los conos derivado de bastones de forma corta y un peptido hidrofilo.
WO2015120542A8 (en) Hybrid proteins and uses thereof
MX2021004470A (es) Vesículas extracelulares para terapias dirigidas contra células supresoras de origen mieloide.
MX2015012281A (es) Proteinas de union a tnf mejoradas.
MX2018003445A (es) Expresion de proteinas que contienen fc.
MX2024005673A (es) Polipeptidos que contienen el dominio d y usos de los mismos.
AR111585A1 (es) Polipéptidos quiméricos y métodos para alterar la localización en la membrana de los mismo